Treatment of leukemia relapse with recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) following unrelated umbilical cord blood transplant: Induction of graft-vs.-leukemia

Pediatric Transplantation

Volumn 6, Issue 5, 2002, Pages 439-442

  Worth, Laura L ^a,b   Mullen, Craig A ^a   Choroszy, Mary ^a   Koontz, Susannah ^a   Chan, Kawah ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Graft vs. leukemia; Infant leukemia; rhGM CSF; Umbilical cord transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DACLIZUMAB; HLA ANTIGEN; HYDROCORTISONE; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ARTICLE; ASCITES; BONE MARROW BIOPSY; CASE REPORT; CELL TRANSPLANTATION; CONGENITAL DISORDER; DIARRHEA; DISEASE COURSE; FEMALE; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFANT; LEUKEMIA; LIVER; NAUSEA; RELAPSE; REMISSION; SKIN; STOMATITIS; UMBILICAL CORD BLOOD; VOMITING;

CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; RECURRENCE;

EID: 0036802497     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2002.02033.x     Document Type: Article

References (8)

1. Harris DT, Locasio J, Besencon FJ. Analysis of alloreactive capacity of human umbilical cord blood; implications for graft-versus-host disease. Bone Marrow Transplant 1994: 14: 545-553.
2. Worth LL, Tran H, Petropoulos D, et al. Hematopoietic stem cell transplantation for childhood myeloid leukemia after high-dose thiotepa, busulfan, and cyclophosphamide. Bone Marrow Transplant 1999: 24: 947-952.
3. Przepiorka D, Petropoulos D, Mullen CA, et al. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated cord blood transplantation. Bone Marrow Transplant 1999: 23: 1291-1295.
4. Giralt S, Escudier S, Kantarjian H, et al. Preliminary results of treatment with filgastrim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 1993: 329: 757-761.
5. Bassan R, Rambaldi A, Amuru R, Motta R, Barbui T. Unexpected remission of acute myeloid leukemia after GM-CSF. Br J Haematol 1994: 87: 835-838.
6. Bishop MR, Tarantolo SR, Pavletic ZS, et al. Filgastrim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplant. J Clin Oncol 2000: 18: 2269-2272.
7. Howrey RP, Martin PL, Driscoll T, et al. Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia. Bone Marrow Transplant 2000: 26: 1251-1254.
8. Kellihan MJ. Drug formulary review process for Sargramostim and Filgrastim: Focus on analysis of adverse drug reaction. Clin Ther 1993: 15: 827-937.